Indian Journal of Health and Allied Sciences (IJHAS)
Journal homepage: https://ijhas.varnavpublishers.com/

Review Article

Novel Drug Therapies in General Health Care: A Review of Efficacy and Safety

Sameer Rastogi[1], Niharika Mishra[2], Keshchandra Singh[3], Vaishnavi Singh[4], Vipul Chaturvedi[5], Sandhya Singh[6]

[1]Professor & Dean, School of Pharmacy, Noida International University, Greater Noida, India
[2]M.Sc. Nursing Tutor (Mental Health Nursing) GSRM Memorial institute of Nursing & Paramedical sciences and Hospital, Uttar Pradesh, Lucknow niharikamishraroli@gmail.com
[3]Assiatant Professor, School of Nursing, Sanakriti University Chatta, Mathura, U.P.
[4]Assistant professor, GSRM memorial institute of nursing & paramedical sciences Lucknow
[5]Nursing Tutor, B.Sc. Nursing College, NMCH Patna, Bihar
[6]Principal B.Sc. Nursing college NMCH, Patna

Abstract

By enhancing patient outcomes, lowering side effects, and improving disease management, novel pharmacological therapies have revolutionized general healthcare. Innovative treatments such biologics, monoclonal antibodies, gene therapies, and drugs based on nanomedicine have been developed as a result of advances in biotechnology, pharmacogenomics, and targeted drug delivery systems. Although these therapies are more effective than traditional treatments, there are still issues with accessibility, cost, and safety. The findings suggest that while novel therapies significantly improve disease prognosis, careful monitoring and regulatory evaluation are essential to ensure patient safety.

Keywords: Novel drug therapy, efficacy, safety, biologics, pharmacogenomics, nanomedicine, healthcare innovation

INTRODUCTION

With the advent of innovative medication therapies that seek to overcome the drawbacks of conventional pharmacological treatments, healthcare has made tremendous strides in recent years. Conventional medications can have systemic side effects and frequently lack specificity, which can result in less than ideal patient results. On the other hand, contemporary therapeutic strategies including gene-based medicines, targeted therapies, and biologics offer precision in the management of illness.[1]

By integrating pharmacogenomics, medical practitioners can customize therapies based on each patient's unique genetic profile, increasing medication efficacy and reducing side effects.[2] Furthermore, the targeted action and bioavailability of drugs have been enhanced via nanotechnology-based drug delivery systems.[3] Despite these advancements, concerns regarding long-term safety, high costs, and regulatory challenges remain significant[4].

Literature Review

This review article is based on a structured analysis of previously published literature obtained from peer-reviewed journals, clinical trial reports, and electronic databases such as PubMed and Google

Address for Correspondence: Dr. Sameer Rastogi Professor & Dean School of Pharmacy, Noida International University, Greater Noida, India E-mail: dean.sop@niu.edu.in

How to cite this article: Rastogi S, Mishra N, Singh K , Singh V, Chaturvedi V, Singh S. Novel Drug Therapies in General Health Care: A Review of Efficacy and Safety. Indian J Health Allied Sci. 2026;1(1):01-03.
Received: 23/03/2026 **Accepted:** 30/03/2026 **Published:** 31/03/2026

Access this article online
Quick Response Code
Website: https://ijhas.varnavpublishers.com/

Scholar. Relevant studies were identified using keywords including "novel drug therapies," "efficacy," and "drug safety." Articles published between 2015 and 2024 were included to ensure updated and relevant evidence. Both randomized controlled trials and observational studies were considered to evaluate the efficacy and safety of emerging drug therapies.[5]

Types of Novel Drug Therapies

- **Biologics and Monoclonal Antibodies**

  Biologics, which come from living things, are frequently utilized to treat long-term illnesses like cancer and autoimmune diseases. Monoclonal antibodies improve therapy outcomes by targeting disease-causing cells specifically.

- **Gene Therapy**

  In order to treat or prevent diseases, gene therapy entails changing or replacing damaged genes. It has had encouraging outcomes in specific types of cancer and genetic abnormalities.[7]

- **Nanomedicine:**

  Targeted drug delivery is made possible by nanotechnology, which also lowers toxicity and increases therapeutic efficacy. Nanocarriers improve drug stability and controlled release.[8]

- **Pharmacogenomics-Based Therapies**

  These therapies customize drug treatment based on genetic makeup, ensuring maximum efficacy with minimal side effects[9].

Efficacy of Novel Drug Therapies

When compared to conventional treatments, novel therapies have proven to be more effective. In chronic illnesses, targeted medicines enhance survival rates and slow the course of disease.[10] Through the alignment of therapy with patient-specific characteristics, personalized medicine approaches further optimize treatment outcomes.[11]

Safety Concerns and Adverse Effects

Novel medication therapy have advantages, but they often come with hazards. Gene treatments may result in unwanted genetic changes, whereas biologics may trigger immune-related adverse responses. Due to the lack of long-term safety evidence, post-marketing surveillance and ongoing monitoring are required.[12]

Discussion

A paradigm change in general healthcare has occurred with the advent of new pharmacological therapy. Improved efficacy and focused treatment are provided by these innovations, but they also come with drawbacks such high cost, accessibility problems, and safety concerns. Healthcare providers and policymakers must strike a balance between patient safety, affordability, and innovation.

Conclusion

Because they provide more efficient and focused treatment alternatives, novel pharmacological therapies have greatly improved the quality of healthcare. Despite their proven effectiveness, safety issues and financial considerations need to be carefully taken into account. To promote optimal use in general healthcare, future research should concentrate on cost-effectiveness, equitable access, and long-term safety evaluation.

Acknowledgement

The author expresses gratitude to all participants and institutions.

Financial Support and Sponsorship : Nil

Conflict of Interest : None

Recommendation

- Post-marketing surveillance should be used to examine the long-term safety of novel pharmacological therapy.
- To increase accessibility in general healthcare settings, cost-effective measures should be created.
- Advanced therapeutics including gene-based treatments and biologics should be taught to medical practitioners.
- To determine long-term efficacy and safety, more extensive clinical trials are needed.

  The creation of regulations for the ethical and safe application of novel pharmaceutical treatments should be the primary goal of policymakers.

References

1. Smith J, Brown K. Advances in targeted drug therapies. J Clin Med. 2019;8(4):456-462.
2. Johnson L, Wang P. Pharmacogenomics in modern medicine. Pharmacology. 2020;15(2):120-128.
3. Gupta R, Sharma M. Nanotechnology in drug delivery. Int J Nanomedicine. 2018;13:2341-2352.
4. Lee A, Kim D. Challenges in novel drug development. Drug Saf. 2021;44(5):567-575.
5. Patel V, Singh S. Research methods in healthcare review studies. J Med Res. 2017;10(3):145-150.
6. Clark H, Adams R. Biologics in chronic disease management. Lancet. 2019;394(10203):123-130.
7. Miller T, Green E. Gene therapy applications. Nat Med. 2020;26(1):15-25.
8. Verma N, Das S. Nanomedicine and its applications. Drug Deliv. 2018;25(1):120-130.
9. Kumar A, Roy P. Personalized medicine and pharmacogenomics. Clin Pharmacol. 2021;9:89-98.
10. Wilson J, Carter B. Efficacy of targeted therapies. Oncol Rev. 2022;16(2):200-210.
11. Singh R, Mehta N. Personalized healthcare approaches. J Health Sci. 2023;12(1):45-52.
12. Brown T, Scott L. Safety concerns in gene therapy. Bioethics. 2019;33(6):678-685.